|
| |
BioJournal - Business Insights Reports
 |
Business Insights' portfolio of pharmaceutical outsourcing management
reports are designed to help you make well informed and timely business
decisions. We understand the problems facing today's pharmaceutical and
healthcare executives when trying to drive your business forward, and
appreciate the importance of accurate, up-to-date, incisive product, market
and company analysis. We help you to crystallize your business decisions.
The strength of our research and analysis is derived from access to
unparalleled databases and libraries of information and the use of
proprietary analytic techniques. |
|
|
The modulation of immune system activity is a required pharmacological
intervention for many medical conditions, bearing particular importance in
the treatment of autoimmune diseases and allergies and transplant
procedures. With traditional immunomodulatory drugs continuing to exhibit
limited efficacy and adverse side effects, the drive to develop new,
improved, and specifically targeted immunotherapies has been gaining
momentum. |
|
|
Drug developments in the US and EU are becoming increasingly expensive
and time consuming, with new products typically requiring investment of over
4 years and $1billion from concept to commercialization. As a result, China
has emerged as an increasingly attractive option for companies aiming to
reduce such prohibitive investments in time and finance. Human clinical
studies have historically dominated outsourced R&D activities in China, with
the country’s relative lack of capital and expertise being insufficient to
facilitate technologically intensive discovery and pre-clinical work. |
|
|
As the pharma industry continues to experience rising research costs,
drug failures and low returns on investment, companies who are increasingly
facing major patent expiries and scarcely populated late-stage pipelines
have accelerated efforts to enhance the speed and efficiency of drug
research. Translational science has emerged as a concept that is set to
revolutionise the traditional R&D paradigm by integrating drug discovery and
development, areas with previously limited interaction. |
|
|
The contract biomanufacturing market achieved a value of $2.5bn in 2006,
with growth expected to continue at an annual rate of 0- 5% until at least
20. The proportion of biologics in new drug approvals has risen by over 30%
during the last decade, and with the current pipeline containing more than
500 protein and 50 peptide developmental drugs, this trend is set to
continue. The commercial success of over 350 approved biologics has prompted
the biotechnology industry to accelerate discoveries in further
protein-based therapeutics, placing greater emphasis upon the importance of
biomanufacturing. Many biotechnology companies are faced with limited
resources, and as large-scale manufacturing continues to intensify, deciding
whether it should be internalised or outsourced to partners or CMO’s is
increasingly crucial in the development of a biotech firm. |
|
|
RNAi-based screens have provided new opportunities for the discovery and
validation of novel therapeutic targets in areas such as cancer and
infectious diseases. Since 2005, enormous strides have also been made in the
development of RNAi-based therapeutic products, bringing them significantly
closer to the market.
‘Outlook for RNAi 2007’ is a new report which provides a detailed insight
into the most effective use of this novel technology in the drug discovery
and development process. It puts into context where RNAi technology is being
used as a tool of choice within academia and the pharma industry for
functional genomic studies, drug target discovery and mechanism of action
studies. The development status RNAi based therapeutics is covered in
detail, highlighting the key companies in the field, outlining their
pipelines and describing the results of completed clinical trials. |
|
|
The global pharmaceutical pricing and reimbursement environment is
notoriously complex and continuously changing. Pharma companies must
implement strategic pricing assessments across global markets and product
lifecycle phases in order to develop effective pricing policies. By
incorporating such assessments into portfolio evaluations and lifecycle
planning, companies can enhance their understanding of potential price
profiles for individual drugs and optimise future returns. |
|
|
As the GIT Market begins to feature increasingly high levels of generic
competition, the focus of pharmaceutical R&D strategies has shifted towards
new therapy areas such as Crohn’s disease and Irritable Bowel Syndrome
(IBS). Although such shifts are becoming the driving force for market
transformation, growth rates may remain low due to the increased
availability of effective generic medicines and fewer launches of innovative
new drugs. |
|
|
CNS disorders constitute one of the most significant components of
healthcare spending in the developed world, contributing to an estimated 35%
of the disease burden within the seven major pharma markets. However, an
increased presence of generic products and lack of innovative product
launches have prompted a slowdown in market growth, which pharma and biotech
companies are addressing through a shift in R&D focus towards disease areas
with relatively low levels of innovation, such as Alzheimer’s and
Parkinson’s disease. |
|
|
The growth of emerging pharmaceutical markets remains impressively
buoyant, having attained a 14.7% value increase over the 2005-06 period, a
substantially greater rate than those witnessed within the developed markets
of the EU and US. Although emergent markets proffer access to sizeable
patient populations, significant barriers to entry continue to exist. |
|
|
Despite significant advances in prevention and treatment, cardiovascular
disease remains the leading cause of death in economically advanced
countries. The developing world has also begun to experience a disconcerting
growth in prevalence, where the insurgence of CVD has exacerbated the risk
factors associated with indigenous communicable diseases. Keeping pace with
epidemiological change in both the developed and developing world
constitutes the overriding challenge for industrial players, and involves
successfully integrating into localised healthcare systems and reimbursement
structures, in addition to remaining aligned with product demand. In the
medical device, pharmaceutical and biotechnology industries, this challenge
is being met with a focus on products that reduce adverse effects, improve
patient outcomes and extend the range of formulations for existing
indications. ‘Innovations in Cardiovascular Disease Management’ is a new
report published by Business Insights that will examine the major
developments shaping the future of the cardiovascular industry. This report
will analyse the future potential of new and emerging products from the
medical device, pharmaceutical and biotechnology sectors, and measure their
likely impact upon the existing market. The extent to which these products
can stimulate the growth and development of the future market will also be
assessed. Use this report to evaluate the potential of new and emerging
products in the treatment of cardiovascular diseases, assess the strength of
competitor pipelines and identify future market opportunities. |
|
|
Biotechnological products are continuing to exhibit substantial revenue
gains, with the top 12 biologics registering sales growth of 20%in 2006,
amassing a market share of $64 billion. However, the impending patent expiry
of many leading products has created a number of highly attractive market
opportunities for biosimilars. To exploit this significant potential, a
complex route to market must first be negotiated, including numerous
barriers to entry and regulatory hurdles. Prominent obstacles include the
sizeable investments in time and expertise associated with biosimilars
development, in addition to the fundamentally higher levels of cost and risk
incurred by manufacturers. Legislative restraints in the US and a recently
established regulatory framework in the EU have also contributed to
industrial obtrusiveness, but for those developers who persevere,
biosimilars are set to offer lucrative returns. The Future of Biosimilars:
Key opportunities and emerging therapies is a new report published by
Business Insights, examining the current market and regulatory environment
for biosimilars in Europe, India, China and the US, whilst identifying the
trends that will shape future market development. |
|
|
Autoimmune related disorders continue to maintain prominence within the
global disease burden, having achieved a worldwide market growth of 9.4%
over the 2002-06 period. However, the inherent threat of generic competition
and novel product launches are forecast to transform the dynamics of the
autoimmune market over the next 5 years. The autoimmune pipeline represents
a key opportunity for drug development companies, with the potential for
success largely attributable to substantial unmet demand, a significant
patient population and the medical proclivity for long term treatments. In
consequence, the effective exploitation of market potential is becoming
increasingly crucial, and hinges upon drug developments that accurately
reflect the shifting demographics of autoimmune disorders and unmet patient
needs. Autoimmune Market Outlook to 2012 is a new report published by
Business Insights, examining how the competitive dynamics of major pharma
companies will influence the market positions of products and shape the
direction of future global autoimmunology. Market trends and leading brands
of treatment are extensively profiled, while the most commercially promising
R&D therapies are investigated and assessed to discover their sales
potential. This report will also provide a comprehensive epidemiological
analysis of the major indications and detailed product sales forecasts. Use
this report to identify opportunities in the autoimmune pipeline, assess the
dynamics of leading competitors and evaluate the impact of key trends across
the global market. |
|
|
In a market environment where competition from generics companies is
becoming increasingly aggressive, and the patenting of therapeutics is
continually subject to impending legislative change, understanding how to
effectively reassess, develop and exploit patent protection strategies is
essential in facilitating enhanced market exclusivity and revenue returns
over the lifecycles of new drugs. Patent Protection Strategies: Maximising
product revenues is a new report published by Business Insights that
examines the need for optimising and sustaining the patent protection of
novel products. The best methods of exploiting legislation to maximise
revenue generation and protecting the considerable investments associated
with innovations are also explored. It will also investigate both the
offensive and defensive tactics that can develop product lifecycle
strategies, through the refinery of organisational patent protection in
tandem to encumbering the market entry of generic substitutes. Develop and
apply successful patent protection strategies, exploit legislation
effectively and secure the lifecycles of your innovations with this new
report |
|
|
Shifting epidemiological demographics within the HIV marketplace,
increasing resistance to current therapies and unmet needs within the
patient population...only an intrinsic understanding of these issues can
secure the commercial success of new drug developments. ‘The Global HIV/AIDS
Market Outlook to 2012’ is a new management report published by Business
Insights that provides comprehensive coverage of the global HIV/AIDS market,
incorporating a detailed epidemiological analysis of the prevalence of
HIV/AIDS and key factors impacting prevalence in both the seven major
pharmaceutical markets as well as emerging markets. This report analyses
current leading brands of treatment within the HIV market, provides
invaluable insights into market dynamics, profiles the leading
pharmaceutical companies and details the key market trends influencing
product sales. This new report will enable you to plan more effectively,
evaluate key changes in the competitive landscape and identify potential
growth areas in the global HIV/AIDS market. |
|
|
Report overview Key findings
Drug repositioning is regarded as the pharma industry’s solution to falling
R&D productivity and weakening product pipelines, successful repositioned
drugs such as raloxifene (Evista; Lilly), thalidomide (Thalomid; Celegene),
(Exubera;Pfizer/Nektar) have enabledinnovative companies to adopt lower risk
strategies to optimize product pipelines. Drug Repositioning Strategies is a
new report that provides in-depth analysis of leading pharma companies that
are using novel technologies to reposition failed, marketed or reformulated
compounds. This report analyzes strategies that are currently being employed
by the leading players and the associated opportunities and challenges
arising from them, enabling you to understand trends in the market and
optimize your R&D pipeline. Use this report to examine current approaches to
drug repositioning and identify successful technologies and business models
that can help your organization deliver enhanced clinical and commercial
output. |
|
|
The highly dynamic cancer market is creating a new age of discovery and
innovation driven by molecular biology, oncogenomics and new methods in cell
biology. Resultantly, cancer innovatives are not only the fastest growing
segment within the cancer market, but the key drivers of sales growth across
the pharmaceutical market as a whole. |
|
|
Traditionally, the Indian pharmaceutical industry has been characterized by
a core competency in generics’ manufacturing and relatively immature
capabilities in R&D. This outlook has evolved substantially since the 1990s
and Indian companies have been making investments towards expanding drug
discovery and development capabilities. The acceptance of patent laws and
the rise of contract manufacturing have led to the diversification of
revenue streams, enabling Indian pharma companies to experience high market
growth. |
|
|
The anti-infectives market is forecast to expand at a CAGR of 4.8%over
the period 2005-11, driven largely by gains in the anti-bacterial and
anti-viral classes. This represents significant market opportunity for
pharma companies to expand their sales potential by targeting high growth
markets. ‘The Global Anti-Infectives Market Outlook to 2011’ provides
comprehensive coverage of the anti-infectives market, incorporating a
detailed epidemiological analysis of the major indications and the key
factors impacting their prevalence. Analysis of the major brands and
profiles of the leading pharmaceutical companies will ensure that you can
plan effectively, evaluate key changes in the competitive landscape, and
identify potential growth areas within the global anti-infectives market.
Use this report to assess anti-infective therapies that will be crucial to
maintaining positive sales growth, analyze the marketed product portfolio
and R&D pipelines of the leading 10 pharmaceutical companies in the global
anti-infectives market. |
|
|
With increased pricing pressure from generics, limited differentiation
among new medicines and pipeline products and declining sales growth, the
women’s health market is facing threatening competitive forces, prompting
major pharmaceutical players to initiate key strategic changes. ‘The Women’s
Health Market Outlook to 2011’ is a new report providing analysis of the
current and future market for women’s health drugs across all major
indications. Forecasts are given based on current marketed portfolio,
drivers and resistors of growth and R&D pipelines, enabling you to predict
changes in the dynamics of the global women’s health market. Key indications
covered in this report are osteoporosis, infertility, uterine fibroids,
endometriosis, urinary incontinence and gynecological infections. |
|
|
With pharmaceutical R&D continuing to suffer from declining productivity
levels and stagnant returns on investment, effective, flexible and
commercially successful new product launches have become more important than
ever. How pharma companies drive product uptake and the effectiveness of
their competitive positioning during the launch phase increasingly define
pharmaceutical market success. ‘Winning Product Launch Strategies’ is a new
report featuring case studies of successful product launches of several key
drugs. The results of 163 new product approvals and launches conducted
across the US and EU are analyzed to provide up-to-date information on
trends in new drug launches along with key factors for successful launches.
Use this report to gain a comprehensive understanding of current and future
product launch strategies, discover key differences between US and EU
approaches and identify current best practices for successful product
launch. |
|
|
Due to shrinking pipelines and rising financial pressures on
pharmaceutical companies, indication expansion is an increasingly attractive
strategy to expand patient potential and extend market exclusivity.
Indication Expansion is a new report that provides in-depth case studies
analyzing successful recent indication expansions and emerging trends. This
report will enable you to avoid potential pitfalls whilst gaining a
comprehensive review of how to delay generic competition and boost revenue
growth. Use the case studies in this report to identify best practice
examples of indication expansion strategies and ensure that you can
implement these into your current processes to maximize the lifecycle of
your products. |
|
|
‘The Dermatology Market Outlook to 2011’ provides detailed analysis on 5
indications within the dermatology market, identifying high growth brands,
future market leaders and key drug classes. The in-depth 6-year epidemiology
and product sales forecasts in this report will enable you to plan
effectively, evaluate changes in the competitive positions of leading
companies and accurately benchmark your position. The 5 Major dermatological
indications covered are acne, psoriasis, infectious diseases of the skin,
dermatitis, rosacea. |
|
|
The online channel offers a key opportunity for pharma companies to
restructure their sales and marketing model, improving their relationships
with physicians and increasing compliance among patients. At the same time,
patients are demanding a greater role in treatment decisions and seeking
information from a range of online sources, resulting in a new age of
consumerism in healthcare. eHealth solutions for Pharma is a new report that
provides an overview of the changing pharma market place, providing
solutions on effective three way communication between pharmaceutical
companies, patients and physicians. Online strategies such as eDetailing,
eSampling, eCME and eCompliance are explored, enabling you to gain best
practice advice on the opportunities offered by eHealth technologies. Use
this report to identify ways to increase productivity and improve
communications between your company, physicians and patients, and implement
eHealth strategies to ensure your products achieve commercial success. |
|
|
The number of commercially lucrative drugs coming off patent has
catalyzed the growth of the generics industry, creating significant profit
opportunities for generics manufacturers. However, this market faces a
considerable number of threats, with bulk manufacturers from developing
countries becoming internationally competitive and the aggressive actions of
branded pharmaceutical marketers in protecting their patent and market
position resulting in ramifications for the sector as a whole. Future Growth
Opportunities in Generics provides an in-depth analysis into the direction
of the global generics market, evaluating competitive dynamics through a
detailed review of major consolidation activity in the sector. Opportunities
for future success are also explored, including the potential offered by
biosimilars and the increasing focus by governments on healthcare cost
containment, enabling you to determine the factors crucial to your success
in the global generics market. |
|
|
Drug delivery is one of the most dynamic and fast growing sectors of the
pharmaceutical industry; the high level of innovation in this sector is
evolving at a fast pace with products such as Pfizer’s inhaled insulin,
Exubera, gaining US approval in January 2006. ‘Innovation in Drug Delivery’
provides an in-depth examination of product launches and pipeline drugs with
novel drug delivery mechanisms set to revolutionize the market, such as
products using ALZA Corporation’s E-TRANS and Altea’s PassPort patch
transdermal technologies. This report will enable you to evaluate key
marketed drugs, including Emend and Megace, and gain an insight into novel
pipeline products to anticipate upcoming product launches and position
yourself for success. Use this report to understand how nanotechnology and
other key technologies are changing drug delivery and how these can be
implemented into your R&D process. Assess the impact of innovation in
therapy areas including oncology, diabetes and infectious diseases and
identify future opportunities for market growth. |
|
|
Today, consumers are taking a more proactive approach to managing their
health and the prevention of diet-related diseases, such as obesity,
diabetes, cardiovascular and bone and joint diseases. Many of these diseases
are at epidemic levels, and this combined with increasing patient power
makes the prevention of these lifestyle diseases attractive markets for both
the food and pharmaceutical industries to exploit. Next-Generation
Nutraceuticals is a new report published by Business Insights that provides
analysis of how the food and pharmaceutical industries are becoming more
aligned in their approach to consumer health. This report assesses the
changing regulatory landscape in addition to how the strategies of leading
ingredients, food, drinks and pharmaceutical companies are evolving in the
new consumer health marketplace. Understand how food and drinks
manufacturers are applying genomic and proteomic technologies that are
widely used in the pharmaceutical industry in order to create increasingly
sophisticated functional food products with this new report. |
|
|
The CNS drug market presents significant profit opportunities, but also
carries high risks for companies aiming to achieve blockbuster status;
pipelines based on novel molecular targets to treat underlying disease
promise to transform the treatment of psychiatric and neurological diseases,
however research and development of these drugs requires an innovative
approach to ensure investment is maximized. ‘Innovations in CNS: Novel
therapeutics and future R&D strategies’ assesses novel treatments in
development for major CNS disorders, comparing them with existing
medications in terms of unmet need and forecasting their success in the
commercial market. This report will enable you to understand the research
tactics of your competitors and develop winning strategies for future growth
in the lucrative CNS market. The report provides a survey of the pipelines
of all of the major players in the CNS area. Detailed company profiles
featured in the report include: AstraZeneca, GlaxoSmithKline, Merck &Co,
Pfizer, and Sanofi-Aventis. Use this report to understand the factors that
will ensure your product pipeline achieves clinical and commercial success
and analyze the product pipelines of the leading companies in the CNS
market. |
|
|
The Cardiovascular Market Outlook to 2011 is a new report from Business
Insights providing analysis of the current and future market for
cardiovascular drugs across all major indications. Forecasts are given based
on new product launches, upcoming patent expiry dates, and ongoing clinical
trials to enable you to predict changes in the dynamics of the global
cardiovascular market. This report offers insight into R&D trends in the
cardiovascular market, including the discontinuation of key pipeline drugs
such as Pfizer’s torcetrapib and atorvastatin, and the development of new
drug classes including Novartis’Rasilez (aliskiren), anticipated to be the
first to market direct renin inhibitor. Use this report to identify the
leading cardiovascular companies to 2011 and discover the cardiovascular
blockbusters of the future. |
|
|
The cancer market is highly dynamic, creating a new age of discovery and
innovation driven by molecular biology, oncogenomics and new methods in cell
biology. These innovations will result in high value opportunities to
develop newer and more effective therapies, ensuring companies can
effectively respond to the increasing prevalence of cancer. ‘Innovations in
Cancer’ provides a detailed insight into the evolution of the cancer market,
the drivers and resistors of innovation and in-depth analysis of advances in
both cancer therapeutics and diagnostics to provide a complete picture of
how the cancer market will develop over the next five years. It also
identifies key alliance and partnering opportunities highlighting companies
with specialised capabilities in the discovery and the characterization of
next-generation drug targets. Use this report to understand how the cancer
market is developing, identify areas of unmet medical need and align your
product pipeline to achieve clinical and commercial success. |
|
|
Metabolomics - the new ‘omics’ - is a dynamic and emerging field,
joining genomics, transcriptomics and proteomics in enabling an integrative
systems biology approach to drug discovery and development. Although
metabolomics is still at an early evolutionary stage it is forecast that
over the next decade the biopharma industry will apply this technology more
widely in drug development and data obtained will be used in drug filing and
optimizing the lifecycle management of marketed drugs. |
|
|
Psychiatric and neurological disorders constitute as much as 35%of the
disease burden in the seven major pharmaceutical markets, representing
continuing opportunities for pharma companies in the CNS market. However,
the increasing presence of generic products coupled with low levels of
innovative launches has resulted in a slowdown in market growth and
considerable unmet need across the spectrum of CNS disorders. ‘The CNS
Market Outlook to 2011’ provides comprehensive epidemiological analysis of
the major CNS indications and key factors impacting market and competitive
dynamics. This report will enable you to identify growth brands, key drug
classes and leading companies through to 2011 ,pin-pointing market trends
that will influence future sales of treatments within the CNS market.
Evaluate changes in the competitive positions of the leading companies in
the CNS market and ensure your R&D pipeline is aligned with future market
opportunity to maximize commercial success. |
|
|
Innovation is the key driving force in the cancer market, creating
strong opportunities for biotech and pharma companies to launch new products
and benefit from high volume sales and a strong competitive position. ‘The
Cancer Market Outlook to 2011’ provides detailed analysis on 9 indications
in the cancer market, identifying growth brands, key drug classes and
leading companies. The 6-year epidemiology and product sales forecasts
detailed in this report will enable you to evaluate the changes in the
competitive positions of leading companies in the cancer market and ensure
your R&D pipeline is aligned with future market opportunity to sustain
revenue growth. Use this report to benchmark the strategies behind the
market-leading products of today and identify which products will be best
positioned for growth over the period 2006-2011. |
|
|
While the specialty pharma sector has traditionally capitalized on
opportunities from Big Pharma, competitive pressure and the maturing market
is forcing them to develop new specialization strategies. These pressures,
such as commoditization of drug delivery technologies and competition from
foreign bulk generics manufacturers, are driving new company growth models
and a focus on targeted portfolios, stronger late-stage drug development
capabilities, M&A and in-licensing activity. ‘The Specialty Pharma Market
Outlook ’evaluates current specialty pharma models, financial performance,
core strategies and the future outlook of specialty pharma companies. This
report also examines key specialty markets, providing valuable insights into
market dynamics while profiling trends influencing market opportunities in
therapeutic indications. Discover how leaders in the specialty pharma market
are achieving high growth, benchmark your strategies against those of the
industry ’s leaders and identify profitable partnering opportunities with
the help of this new report. |
|
|
In today’s competitive environment, alliances are critical for
pharmaceutical companies to optimize R&D and marketing synergies and share
risks in order to develop pipelines. Companies must maximize their licensing
and alliance management capabilities in order to bring new drugs to the
market successfully, while minimizing the potential for failure.
‘Pharmaceutical Strategic Alliances’ provides in-depth case studies focusing
on deal outcomes, and highlights key success factors in agreeing and
executing strategic alliances. The report isolates four key alliance
structures - co-commercialization, co-development, multi-product and joint
ventures - presenting a series of in-depth industry examples providing
critical insights into current best practices and key recommendations for
forming successful strategic alliances. Use this report to understand the
complexities of the various types of strategic alliances, analyze the key
issues and critical success factors behind building and managing effective
alliances and ensure you negotiate the best deal terms for your company. |
|
|
The global diagnostics market is undergoing radical change; novel
technologies driven by miniaturization and advances in genomics will enhance
the role of diagnostics in the healthcare market, allowing more tests to be
performed at the point-of-care and facilitating the shift towards
personalized medicine. “Innovation in Diagnostics” examines the advances in
the rapidly growing field of molecular technologies that are enabling
personalized healthcare to move into mainstream medicine. New opportunities
in infectious disease testing, molecular oncology and pharmacogenomics are
explored in detail, enabling you to understand the forces that are driving
in vitro diagnostics (IVDs) into centre stage of the healthcare arena.
Understand the changing relationship between IVD companies and the
pharmaceutical industry, assess the convergence of IVDs and medical imaging,
and develop an understanding of new technologies that will influence
diagnostic product development and drug development programs. |
|
|
Positive economic growth, stabilizing political structures, growing
patient populations and increasing direct foreign investment in the emerging
markets of Brazil, Russia, India and China (BRIC) are creating significant
opportunities for pharmaceutical companies to expand into these markets and
maximize future revenue potential. Pharmaceutical sales across the BRIC
economies grew by 22.3%in 2005, compared to single digit growth in the major
markets of the US, Europe and Japan. This new report provides an in-depth
insight into the competitive dynamics of the BRIC markets. The political and
regulatory environments are evaluated and healthcare systems assessed,
enabling you to understand the determinants crucial to your success in these
high growth markets. Benchmark your growth strategies against the top
pharmaceutical companies operating in the BRIC markets, align your portfolio
with future market opportunity and identify lucrative partnering
opportunities to ensure you maximize the potential from these promising
markets.
Published: August 2006 |
|
|
The market for therapeutic monoclonal antibodies (mAbs) is one of the
most dynamic sectors within the pharmaceutical industry; next generation
antibodies are forecast to drive the market towards the $30 billion mark by
2011 due to a high level of innovation in early-stage discovery and several
potential nichebusters set to launch in the next 5 years. ‘The Future of
Monoclonal Antibody Therapeutics: Innovation in antibody engineering, key
growth strategies and forecasts to 2011’ is a unique report that combines
up-to-date analysis of the current antibodies market with detailed insights
into therapeutic, technology, discovery and drug delivery trends set to
shape the market in the next 5 years and beyond. Gain access to the most
comprehensive data on the antibody market and take advantage of exclusive
insights into research trends from early stage discovery to marketed drugs. |
|
|
The RNAi market achieved global sales of just over $1bn in 2004 and is
projected to reach $2.5bn by 2010,a compound annual growth rate
(CAGR)2004-2010 of 14%.‘The Outlook for RNAi: Accelerating drug discovery
and the development of RNAi therapeutics’ analyzes the latest trends in the
RNAi market, allowing pharmaceutical companies to decide which areas of RNAi
technologies to invest in, to improve drug attrition rates and develop new
therapeutic agents. RNAi therapeutics are forecast to generate sales of
around $1bn by 2015 and this market has significant potential, should
companies be able to overcome delivery constraints. |
|
|
The prevalence of asthma in 2005 across the US, Japan, France, Germany,
Spain, Italy and the UK was estimated at 53.2m people, corresponding to a
prevalence rate of 7.7%. The highest prevalence rate for asthma in any
country in 2005 was 12.0% in the UK. It is forecast that by 2011, the total
prevalence of asthma across the seven major markets will be 58.8m sufferers
or 8.0% of the population. COPD is only significantly prevalent in adults, a
contrary situation to that of asthma, in which pediatric patients are
estimated to represent some 35% of the total asthmatic patient population
across the 7 major markets. 56.4m individuals are estimated to suffer from
COPD across the seven major markets, although extremely low rates of
diagnosis are thought to have resulted in a treated population of less than
10m individuals. Increasingly, COPD is becoming a major disease burden
across the seven major markets, with a forecast patient population of 60.8m
individuals by 2011, indicating high levels of future patient potential.
Currently the treatment of asthma/COPD favors the use of beta-2 agonists and
inhaled corticosteroids, with leukotriene antagonists and anticholinergics
being positioned as additional therapies in either pediatric or last-line
patients. |
|
|
With falling R&D productivity and continued healthcare cost containment
and generic competition pushing down the returns available for successfully
launched products, only those companies able to complement internal efforts
with a strong partnering strategy will be able to remain competitive over
the next five-to-ten years. Pharmaceutical licensing strategies: Best
practices in deal-making, valuations and strategic management provides a
detailed analysis of licensing strategies in the pharmaceutical and
biotechnology industries. The report draws upon deal-making trend data,
primary research survey results and a profile of best practices in
pharmaceutical licensing in order to present a set of actionable
recommendations for optimizing deal-making. |
|
|
The patient populations for neuropathic and nociceptive pain are large,
and are driven by separate disease trends that necessitate pain relief;
across the seven major markets in 2005 it was estimated that 37.6m
individuals suffered from neuropathic pain and 170.1m suffered from
nociceptive pain. The major constituents of the neuropathic pain market are
lower back pain, neuralgia/fibromyalgia, diabetic neuropathic pain and pain
associated with multiple sclerosis. The nociceptive pain market is driven by
the prevalence of the major indications of arthritic pain, particularly
osteoarthritis and rheumatoid arthritis, post-operative pain, cancer-related
pain and HIV-related pain. Current management of pain is mostly
pharmacological consisting of the use of opioids, non-opioids and
non-steroidal anti-inflammatory drugs (NSAIDs), as well as adjuvant
therapies such as anti-depressants and anti-convulsants. Although pain is
not a new phenomenon, misdiagnosis and under-treatment continue to prove
deleterious to the pain market. Increased education for patients,
physicians, nurses and pharmacists is an on-going unmet need that must be
addressed. Across the seven major markets, it is forecast that the
prevalence of both the neuropathic and nociceptive markets will increase
modestly. It is forecast that the prevalence of the neuropathic pain market
will increase to 39.1m individuals, which is complimented by the forecast
growth of the nociceptive market to include 164.8m individuals in 2011. |
|
|
High clinical development costs coupled with declining drug discovery
success rates have meant that pharmaceutical companies must re-evaluate
their drug development process in order to reduce attrition rates and remain
competitive. Over the next decade biomarkers will change the way in which
pharma companies determine the economic viability of their drug discovery
process. The use of biomarkers to aid the discovery of promising products
will create an enhanced understanding of the clinical development process
and help to facilitate the shift towards 'personalized medicine'.
'Commercial Opportunities from Biomarkers: Transforming drug discovery,
clinical development and molecular diagnostics' is the latest addition to
the drug discovery series, examining recent developments and applications
within the biomarkers field. Using up-to-date case studies to indicate best
practice strategies, this report will ensure that you are able streamline
your R&D process and identify potential cost savings throughout drug
discovery and development. Regulatory changes are analyzed and recent
alliances are examined, enabling you to understand the role and future of
this fast-moving field. |
|
|
Diabetes mellitus is a chronic metabolic disorder that is caused by a
failure of the body to produce insulin and/or an inability of the body to
respond adequately to circulating insulin; type 1 diabetes occurs most often
in children or young adults and accounts for 5-10% of the diagnosed diabetes
patient population. Type 2 diabetes, or adult-onset diabetes, accounts for
90–95% of diagnosed diabetes cases worldwide, typically developing in
middle-aged adults. There are several risk factors associated with type 2
diabetes including age, obesity, high blood pressure, genetics, level of
exercise, and a history of cardiac disease. Type 2 diabetes is more
prevalent than type 1 and is growing at a faster rate across the 7 major
markets, with a forecast prevalence of 49.2m people in 2011, compared to
39.4m people in 2005. Drivers for increased type 2 prevalence include the
aging demographic profile and an increase in obesity. Diabetes is the sixth
leading cause of death in the US (based on number of death certificates,
NIDDK). The global diabetes market was worth $18.6bn in 2005, which was an
11.5% increase from 2004 sales of $16.6bn. The US has the dominant share in
the global diabetes market, with 49.6% of 2005 global sales. The large US
market share is mainly due to the large population and the high prevalence
of diabetes, the increasing incidence of diabetes associated with Western
diets and an aging population. OADs represent 58% of the global diabetes
market in 2005, with the remainder of sales being from insulins and analogs
(40.1%) and other drugs with 1.9%. However, insulins and analogs have seen
the largest sales growth at 17.3% in 2005. There has been a high level of
innovation in drug delivery technology within the diabetes market during
2005-6. Key events include advances in inhaled insulins, funding into
insulin pills, patch technology and pain free needles for injection. The top
10 leading antidiabetic brands consist of 6 OADs (Actos, Avandia, Amaryl,
Basen, metformin HCl, and Avandamet) and 4 insulins (Lantus, Humalog,
NovoLog/NovoRapid and Novolin 70/30/actraphane). |
|
|
The expansion of the EU has created exciting opportunities for
pharmaceutical companies to expand into new territories and take advantage
of these high growth emerging markets; this report analyzes eight of the
accession countries including the Czech Republic, Estonia, Hungary, Latvia,
Lithuania, Poland, Slovakia and Slovenia (The A8). Pharmaceutical Growth
Opportunities in the EU Accession States is a new report which provides
in-depth insights into the competitive dynamics of the EU accession states.
It identifies the key drivers and resistors of growth to enable you to
understand the most important factors behind success in each country market.
Use this latest report to determine key product opportunities, identify
potential alliance partners and plan a successful and sustainable long term
growth strategy to secure your leading position in the next five years. |
|
|
Over the last decade outsourcing has become an important strategic issue
for pharmaceutical companies; rising pressure to reduce costs and
time-to-market has led to outsourcing not only of traditional non-core
functions such as manufacturing and clinical trials, but also increasingly
of technically demanding areas such as drug discovery and biotech R&D. |
|
|
Stem cell transplants are routinely used to treat patients with cancers
and other disorders of the blood and the immune system and may hold the key
to repairing or replacing tissue cells damaged in many devastating diseases.
Thus, proven and potential clinical benefit underpins the vast interest in
stem cell research. Stem cells have both the capacity to self-renew (by cell
division) and differentiate into mature, specialized cells. |
|
|
Branding is a key issue in the pharmaceutical industry; product managers
have evolved into brand managers and are beginning to understand the
dynamics of brand equity that lie at the heart of product development and
marketing. However, with no established ‘best practices’ in brand
management, those tasked with steering brands around the various hurdles and
challenges presented by pharmaceutical markets must use all available
learning and experience to help build the leading brands of the future |
|
|
Researchers in the pharmaceutical and biotech industry have been
developing tools over the years to maximize the efficacy of drugs while
minimizing toxicity, and advances have been made. A decade ago, the number
of drugs failing preclinically due to poor pharmacokinetics was upwards of
40%, but improved in vitro and animal models have reduced that rate to about
10%. |
|
|
The generics sector has grown at a fast pace over the past few years,
outperforming the pharmaceutical market as a whole; generic growth
opportunities are significant, with an estimated $100bn worth of branded
pharmaceutical products to go off patent by 2010, of which $21bn expire in
2006. Although US and major European generic drug sales increased rapidly
from 2000 to 2003, there has been a slowdown in growth during 2004. In
response to an increasingly competitive unbranded generic pharmaceutical
marketplace, and a slowdown in growth in 2004, some of the major generics
players have consolidated. |
|
|
When a branded product loses patent protection, bioequivalent generic
versions of the original compound can be launched by competitors, invariably
at a lower price; this leads to strong competition for the branded product,
which then experiences declining sales and market share. It is not unusual
for product sales to fall by 80% or more after patent expiration if generic
competition is strong. |
|
|
While the human genome project has provided vast amounts of sequence
information, the in vivo functional analysis of thousands of genes has
presented a significant challenge to researchers and to pharmaceutical
companies in the discovery of new drug targets. However, RNAi-based screens
have provided new opportunities for the discovery and validation of novel
therapeutic targets in several disease areas such as cancer and infectious
diseases |
|
|
The study of genes used to be a slow and arduous process with a single
gene studied in a single experiment. The filter and blotting methods used
provided limited information about other genes or how single genes interact
with the collective gene product in a living organism. The advent of DNA
microarrays (also referred to as biochips, DNA chips, DNA arrays, gene
arrays and GeneChipsÒ), which allow analysis of many genes in a single
experiment quickly and efficiently, has transformed research. |
|
|
This report provides a detailed insight into this complex new process
and how it can be used to drive research and development in a variety of
biologically-based industries. The competitive landscape of systems biology
assessed in this report is supported by case studies of leading companies,
enabling you to learn from their experiences and avoid the potential
pitfalls. |
|
|
The pharmaceutical industry has undergone considerable consolidation
during the last 20 years as companies attempt to maintain double-digit sales
growth and shareholder value. Strategic mergers and acquisitions have
resulted in companies revitalizing their drug pipelines to replace
blockbuster drugs that face patent expiration. |
|
|
The Latin American Market Outlook to 2010 is a new management report
which provides comprehensive coverage of the major cardiovascular markets in
the Latin American region. This report provides detailed analysis of market
trends, epidemiology, current leading brands of treatment, product sales
forecast and future market leaders over the period 2005-2010 in ten markets:
Brazil, Mexico, Argentina, Puerto Rico, Chile, Venezuela, Colombia, Ecuador,
Peru, Uruguay. |
|
|
This report provides comprehensive coverage of the major GIT markets,
incorporating a detailed epidemiological analysis of the major indications
and key factors impacting their prevalence; using IMS data, it provides
analysis of current leading brands of treatment within each GIT indication
provides an invaluable insight into the dynamics of the market, while
profiling the pharmaceutical companies and relevant market trends that
influence the sales of GIT treatments. |
|
|
Pharmaceutical branding describes the process whereby companies attempt
to transform an active chemical compound into a recognizable package of
associated brand values; these values, such as effectiveness, safety, trust
and other more emotional associations, have become increasingly important
levers through which pharmaceutical marketers can look to achieve greater
market share and loyalty in an evermore competitive market space. |
|
|
The Asian Cardiovascular Market Outlook to 2010 is a new management
report which provides comprehensive coverage of the major cardiovascular
markets in the Asia Pacific region. |
|
|
The number of patients eligible for cardiovascular therapies is
increasing quickly, and, as in the developed pharmaceutical markets, is
primarily driven by increases in prevalence in diabetes and obesity, trends
that do not appear likely to diminish over the period 2004-10. |
| |
|
